Itacitinib
Tier C — Watch / tradeItacitinib
Targets：JAK2, JAK1
Indications (approved)：Diffuse large B-cell lymphoma, Myeloproliferative neoplasm, Acute lymphoblastic leukaemia, Acute myeloid leukaemia, Chronic myelomonocytic leukaemia, 骨髓增生异常-骨髓增生性疾病, Myelofibrosis, 血小板增多
Regional status
Synthetic routes & intermediates2 routes
Routes are ordered originator first, then optimised / process (non-patent) routes; each lists steps, overall yield and the intermediate table (code / CAS / name) — ready for supplier sourcing and RFQ. Rendered by this site from structured data; no third-party route graphics used.
| Code | CAS No. | Intermediate |
|---|---|---|
| ITACI-001 | 91-00-9 | diphenylmethanamine |
| ITACI-002 | 106-89-8 | 2-(chloromethyl)oxirane |
| ITACI-003 | 90604-02-7 | 1-benzhydrylazetidin-3-ol hydrochloride |
| ITACI-004 | 141699-55-0 | tert-butyl 3-hydroxyazetidine-1-carboxylate |
| ITACI-005 | 398489-26-4 | tert-butyl 3-oxoazetidine-1-carboxylate |
| ITACI-006 | 2537-48-6 | diethyl (cyanomethyl)phosphonate |
| ITACI-007 | 1153949-11-1 | tert-butyl 3-(cyanomethylene)azetidine-1-carboxylate |
| ITACI-008 | 1239322-61-2 | 4-(4,4,5,5-tetramethyl-1,3-dioxolan-2-yl)-1H-pyrazole |
| ITACI-009 | 1153949-15-5 | tert-butyl 3-(cyanomethyl)-3-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazol-1-yl)azetidine-1-carboxylate |
| ITACI-010 | 3680-69-1Available | 4-chloro-7H-pyrrolo[2,3-d]pyrimidine |
| ITACI-011 | 1627504-41-9 | tert-butyl 3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-(cyanomethyl)azetidine-1-carboxylate |
| ITACI-012 | 1627504-43-1 | 2-(3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)azetidin-3-yl)acetonitrile dihydrochloride |
| ITACI-013 | 1334303-99-9 | 1-(3-fluoro-2-(trifluoromethyl)isonicotinoyl)piperidin-4-one |
| ITACI-014 | 42899-11-6 | 1,4-dioxa-8-azaspiro[4.5]decane hydrochloride |
| ITACI-015 | 177-11-7 | 1,4-dioxa-8-azaspiro[4.5]decane |
| ITACI-016 | 886510-09-4 | 3-fluoro-2-(trifluoromethyl)isonicotinic acid |
| ITACI-017 | 1426436-72-7 | (3-fluoro-2-(trifluoromethyl)pyridin-4-yl)(1,4-dioxa-8-azaspiro[4.5]decan-8-yl)methanone |
| ITACI-018 | 288-13-1Available | 1H-pyrazole |
| ITACI-019 | 3469-69-0Available | 4-iodo-1H-pyrazole |
| ITACI-020 | 189332-05-6 | 4-iodo-1-(trimethylsilyl)-1H-pyrazole |
| ITACI-021 | 61676-62-8 | 2-isopropoxy-4,4,5,5-tetramethyl-1,3,2-dioxaborolane |
| Itacitinib | 1334298-90-6 | 2-(3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-1-(1-(3-fluoro-2-(trifluoromethyl)isonicotinoyl)piperidin-4-yl)azetidin-3-yl)acetonitrile |
| Itacitinib Adipate | - | 2-(3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-1-(1-(3-fluoro-2-(trifluoromethyl)isonicotinoyl)piperidin-4-yl)azetidin-3-yl)acetonitrile adipate |
| Code | CAS No. | Intermediate |
|---|---|---|
| ITACI-007 | 1153949-11-1 | tert-butyl 3-(cyanomethylene)azetidine-1-carboxylate |
| ITACI-008 | 1239322-61-2 | 4-(4,4,5,5-tetramethyl-1,3-dioxolan-2-yl)-1H-pyrazole |
| ITACI-010 | 3680-69-1Available | 4-chloro-7H-pyrrolo[2,3-d]pyrimidine |
| ITACI-013 | 1334303-99-9 | 1-(3-fluoro-2-(trifluoromethyl)isonicotinoyl)piperidin-4-one |
| ITACI-018 | 288-13-1Available | 1H-pyrazole |
| ITACI-022 | 1314910-43-4 | 2-(azetidin-3-ylidene)acetonitrile hydrochloride |
| ITACI-023 | 1627504-45-3 | 2-(1-(1-(3-fluoro-2-(trifluoromethyl)isonicotinoyl)piperidin-4-yl)azetidin-3-ylidene)acetonitrile |
| ITACI-024 | 1627504-47-5 | 2-(1-(1-(3-fluoro-2-(trifluoromethyl)isonicotinoyl)piperidin-4-yl)-3-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazol-1-yl)azetidin-3-yl)acetonitrile |
| ITACI-025 | 2075-45-8Available | 4-bromo-1H-pyrazole |
| ITACI-026 | 1024120-52-2 | 4-bromo-1-(1-ethoxyethyl)-1H-pyrazole |
| ITACI-027 | 1195-66-0 | 2-methoxy-4,4,5,5-tetramethyl-1,3,2-dioxaborolane |
| ITACI-028 | 1029716-44-6Available | 1-(1-ethoxyethyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole |
| ITACI-029 | 1193-24-4 | pyrimidine-4,6-diol |
| ITACI-030 | 5305-40-8 | 4,6-dichloropyrimidine-5-carbaldehyde |
| ITACI-031 | 14160-93-1 | 4-amino-6-chloropyrimidine-5-carbaldehyde |
| ITACI-032 | 2092876-49-6 | (E)-6-chloro-5-(2-methoxyvinyl)pyrimidin-4-amine |
| Itacitinib | 1334298-90-6 | 2-(3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-1-(1-(3-fluoro-2-(trifluoromethyl)isonicotinoyl)piperidin-4-yl)azetidin-3-yl)acetonitrile |
Frequently asked questions
What are the approved indications of Itacitinib?
Approved indications include: Diffuse large B-cell lymphoma, Myeloproliferative neoplasm, Acute lymphoblastic leukaemia, Acute myeloid leukaemia, Chronic myelomonocytic leukaemia, 骨髓增生异常-骨髓增生性疾病, Myelofibrosis, 血小板增多.
When does the Itacitinib patent expire?
No public expiry year is available for Itacitinib yet; this page updates once verified.
How many synthesis routes are recorded for Itacitinib?
2 synthesis routes are recorded; the shortest is 12 steps with 135 mg total yield. Intermediates in each route carry codes and CAS numbers.
Where can I buy Itacitinib intermediates?
5 intermediate CAS of Itacitinib are available through the Unibest supply network — see the route tables on this page and request a quote per CAS.
How do I get a quote for Itacitinib intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-18